In 2009, Xerclear® (Zoviduo®) was approved for the treatment of labial herpes. The marketing rights to Xerclear® in the USA, Canada and Mexico were divested in 2010. The corresponding rights in Europe and the rest of the world have been out-licensed to GlaxoSmithKline, with the exception of China, where Medivir has appointed a local distributor, and Israel and South America where Medivir has retained the rights.
Medivir receives royalties on sales of Xerclear®/(Zoviduo®) from GlaxoSmithKline.
Including 2017, the cumulative royalties received thus far amounts to approximately 350 SEK million. In addition, Medivir would receive milestones when Zoviduo® is approved as an over the counter product in certain new markets.